Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: ENSEMBLE trial | Statement: [Janssen COVID-19 Vaccine, clinicalTrialPhase3, ENSEMBLE trial]

Target entity: ENSEMBLE trial
Context triple: [Janssen COVID-19 Vaccine, clinicalTrialPhase3, ENSEMBLE trial]

• A. EMERGE (Study 302)
  EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
• B. ENGAGE (Study 301)
  ENGAGE (Study 301) is a large Phase 3 clinical trial designed to evaluate the efficacy and safety of the anti-amyloid monoclonal antibody aducanumab (Aduhelm) in patients with early Alzheimer’s disease.
• C. ARRAY Alliance
  ARRAY Alliance is a nonprofit organization and social impact collective founded by filmmaker Ava DuVernay to advance racial and gender equity in the entertainment industry and beyond.
• D. Euroradar consortium
  The Euroradar consortium is a multinational industrial partnership responsible for designing and producing advanced airborne radar systems for modern fighter aircraft.
• E. Cordis
  Cordis is a medical device company best known for developing and manufacturing cardiovascular and endovascular products such as stents and catheters.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: ENSEMBLE trial
Triple: [Janssen COVID-19 Vaccine, clinicalTrialPhase3, ENSEMBLE trial]

The ENSEMBLE trial was a large, global Phase 3 clinical study designed to evaluate the safety and efficacy of Janssen’s single-dose COVID-19 vaccine in preventing SARS-CoV-2 infection and severe disease.

Target entity: ENSEMBLE trial
Target entity description: The ENSEMBLE trial was a large, global Phase 3 clinical study designed to evaluate the safety and efficacy of Janssen’s single-dose COVID-19 vaccine in preventing SARS-CoV-2 infection and severe disease.

• A. EMERGE (Study 302)
  EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
• B. ENGAGE (Study 301)
  ENGAGE (Study 301) is a large Phase 3 clinical trial designed to evaluate the efficacy and safety of the anti-amyloid monoclonal antibody aducanumab (Aduhelm) in patients with early Alzheimer’s disease.
• C. ARRAY Alliance
  ARRAY Alliance is a nonprofit organization and social impact collective founded by filmmaker Ava DuVernay to advance racial and gender equity in the entertainment industry and beyond.
• D. Euroradar consortium
  The Euroradar consortium is a multinational industrial partnership responsible for designing and producing advanced airborne radar systems for modern fighter aircraft.
• E. Cordis
  Cordis is a medical device company best known for developing and manufacturing cardiovascular and endovascular products such as stents and catheters.
• F. None of above. chosen

Target predicate: clinicalTrialPhase3
Context triple: [Janssen COVID-19 Vaccine, clinicalTrialPhase3, ENSEMBLE trial]

• A. coordinatesClinicalTrialsFor
  Indicates that one entity organizes, manages, or oversees the planning and execution of clinical trials on behalf of another entity.
• B. phaseIIIDescription
  Indicates that the entity has a textual description specifically about its Phase III stage in a process, study, or project.
• C. hasKeyClinicalTrial chosen
  Indicates that an entity is associated with a primary or pivotal clinical trial that is especially important for its evaluation or approval.
• D. hasPreclinicalFeature
  Indicates that an entity exhibits a characteristic, sign, or attribute that is present before the full clinical manifestation of a condition or disease.
• E. experimentedOn
  Indicates that one entity conducted experiments or tests on another entity as the subject of investigation.
• F. None of above.